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Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against 
factor VIII (FVIII). Treatment with clopidogrel is a cause of AHA, but its clinical course is 
unknown. Recently, we treated a 65-year-old man who was hospitalized for cerebellar 
infarction and had a prolonged activated partial thromboplastin time (aPTT) with soft tis-
sue oozing after 3 weeks of clopidogrel use. We terminated clopidogrel administration 
and transfused the patient with fresh frozen plasma. However, the aPTT increased up to 
98.8 seconds, and the FVIII and FVIII inhibitor levels were ＜1% and 5.4 Bethesda 
units/mL, respectively. Clopidogrel-associated AHA was considered, and we began ste-
roid treatment. Two months later, FVIII, FVIII inhibitor, and aPTT values were normalized. 
No further bleeding or aPTT prolongation has been reported during the 2-year follow-up 
period. AHA should be considered in patients taking clopidogrel and experiencing bleed-
ing, unless the platelet count and coagulation screen are normal.
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INTRODUCTION
Acquired hemophilia A (AHA) is a rare bleeding disorder 
caused by autoantibodies against factor VIII (FVIII) [1]. It 
is diagnosed in patients without previous or familial histories 
of bleeding who have isolated prolongation of the activated 
partial thromboplastin time (aPTT) that cannot be corrected 
by mixing study and who have reduced FVIII levels as well 
as evidence of FVIII inhibitor activity [2]. FVIII autoanti-
bodies occur in patients in the postpartum period and those 
with concomitant diseases or conditions (i.e., autoimmune 
disorders, malignancies, and drug abuse). However, up to 
50% of cases develop without any relevant medical illness 
[3]. The mortality rate of AHA is as high as 16% [4].
Clopidogrel, an antiplatelet agent commonly used for coro-
nary disease or cerebral vascular disease, is a cause of AHA 
[5]. However, only 5 cases of clopidogrel-related AHA have 
been described to date [5, 6]. Because the exact natural history 
of clopidogrel-associated AHA is unknown, knowledge of 
its clinical features is important. The present report describes 
a patient with AHA associated with clopidogrel use who 
showed complete remission after steroid administration and 
discontinuation of clopidogrel.
CASE REPORT
A 65-year-old man was hospitalized for cerebellar infarc-
tion. He was referred to the hematology department due 
to prolonged aPTT. He had been administered aspirin, clopi-
dogrel, and valproate for cerebellar infarction, a statin for 
hyperlipidemia, and cefoperazone, clindamycin, and teico-
planin for aspiration pneumonia. He had no previous or 
familial medical history of bleeding or coagulopathy and 
no clinical symptoms or signs of malignancy, antiphospholi-
pid syndrome, or collagen vascular disease.
At admission, he was drowsy without clinical evidence 
of bleeding. He was intubated, and a tracheostomy was 
performed. Initial laboratory results showed normal com-
plete blood cell counts, kidney and liver function, and coagu-
lation parameters. However, 3 weeks after initiation of clopi-
dogrel, blood oozed from his tracheostomy site, and his aPTT 
was 40.3 seconds (normal range, 27.9-37.8 seconds) (Fig. 
1). Clopidogrel was considered the cause of bleeding, and 
its administration was discontinued. However, blood con-
tinued to ooze from his tracheostomy stoma, and his aPTT 
gradually rose up to 98.8 seconds (Fig. 1) without platelet 
or PT changes despite discontinuation of clopidogrel and Korean J Hematol 2012;47:80-2.
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Fig. 1. Changes in aPTT, FVIII, and FVIII inhibitor levels as well as the use
of blood products or medication after clopidogrel treatment. Abbrevia-
tions: aPTT, activated partial thromboplastin time; FVIII, factor VIII; FFP,
fresh frozen plasma.
a transfusion with fresh frozen plasma. A mixing test did 
not correct the aPTT. Tests for lupus anticoagulant, anti-
cardiolipin antibody, and antinuclear antibody were nega-
tive. His FVIII was below 1% (reference range, 60-140%), 
and his FVIII inhibitor titer was 5.4 Bethesda units/mL 
(BU/mL) (Fig. 1).
We suspected clopidogrel-associated AHA and began ste-
roid administration. Within a few days, the bleeding was 
controlled, and the patient’s aPTT decreased to normal levels. 
However, 3 weeks after steroid use, active bleeding developed 
from his stoma. His aPTT was normal, and FVIII inhibitor 
was undetectable (Fig. 1). However, his FVIII was only 8% 
(Fig. 1). We performed a left inferior thyroid arterial branch 
ligation and administered human FVIII concentrates 
(GreenMono, Greencross, Gyeonggi-do, Korea). Afterward, 
there were no further bleeding episodes, and his FVIII was 
normalized 2 months after steroid treatment. The patient 
was gradually tapered off steroids in 3 months. During the 
2-year follow-up period, his aPTT remained within normal 
levels.
DISCUSSION
Clopidogrel is increasingly used as a first-line antiplatelet 
agent in patients with coronary artery disease, cerebral vas-
cular disease, and peripheral vascular disease [7]. Clopidogrel 
is known to have adverse hematologic effects, such as neu-
tropenia [8, 9], idiopathic immune thrombocytopenia [10], 
thrombotic thrombocytopenic purpura [11], and hemolytic 
uremic syndrome [12]. Recently, 5 cases of clopidogrel-asso-
ciated AHA have been reported [5, 6].
In general, there is an equal distribution of AHA between 
the sexes. However, there is a female predominance in the 
younger age group because of an association with pregnancy, 
and males constitute the majority of patients over the age 
of 60 who develop AHA [13, 14]. However, in 5 cases of 
clopidogrel-associated AHA, 4 were females, and all were 
over the age of 60 years (67-78 years) [6]. Nevertheless, 
a predominance of clopidogrel-associated AHA in females 
is difficult to conclude due to the rarity of the condition. 
It appears more likely to occur in older patients, who tend 
to have vascular diseases and, as a result, more commonly 
use clopidogrel. In the present case, soft-tissue bleeding and 
aPTT prolongation developed within 3 weeks after clopidog-
rel treatment. Because the patient was hospitalized during 
that episode, we were able to detect the abnormal aPTT 
earlier than in 2 previous cases, where AHA developed in 
2-3 months after clopidogrel use [5].
In the literature, there are 34 cases of drug-induced AHA 
with FVIII inhibitor titers ranging from 1.6 to 250 BU/mL 
(average, 67.7 BU/mL) [6]. Those with clopidogrel-associated 
AHA had FVIII titers from 2.2 to 17 [6]. The present patient 
had a FVIII titer of 5.4 BU/mL. However, according to that 
analysis [6], FVIII inhibitor titers were not well correlated 
with FVIII levels or clinical manifestation. In the present 
case, FVIII levels were normalized in about 7 weeks after 
the FVIII inhibitor titer was normalized. This discordance 
may arise from the different pattern of FVIII inactivation 
as a result of autoantibodies in AHA versus alloantibodies 
in congenital hemophilia [15]. In fact, whereas alloantibodies 
usually completely inactivate FVIII activity (type I kinetics), 
autoantibodies often incompletely inactivate FVIII activities 
(type II kinetics), and some residual FVIII activity remains 
in the patient’s plasma [15]. Therefore, the Bethesda assay, 
which quantifies the in vitro inhibitor titer, may under-
estimate in vivo inhibitor potency in AHA [6].
There are no guidelines with respect to treatment for 
AHA, although its mortality rate is as high as 16% [4]. In 
over 80% of the cases, FVIII inhibitor disappeared after dis-
continuation of clopidogrel or after immunosuppressive ther-
apy [6]. The present patient’s FVIII was normalized after 
7 weeks of steroid use. This is similar to 2 cases reported 
by Haj et al., in which FVIII returned to normal levels, 
and FVIII inhibitor was undetectable within 8 weeks of 
steroid treatment [5] and remained normal for 2 years. 
Therefore, bleeding tendencies in patients using clopidogrel 
should not be regarded as an antiplatelet effect of clopidogrel 
unless a platelet count and coagulation screen are normal. 
Immunosuppressive therapy should be initiated as soon as 
AHA is diagnosed.
REFERENCES
1. Green D, Lechner K. A survey of 215 non-hemophilic patients 
with inhibitors to factor VIII. Thromb Haemost 1981;45:200-3.
2. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. 
Acquired haemophilia: review and meta-analysis focused on Korean J Hematol 2012;47:80-2.
82 Hye Won Hwang, et al. 
therapy and prognostic factors. Br J Haematol 2003;121:21-35.
3. Toschi V, Baudo F. Diagnosis, laboratory aspects and management 
of acquired hemophilia A. Intern Emerg Med 2010;5:325-33.
4. Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of 
acquired hemophilia by the Bonn-Malmo Protocol: documen-
tation of an in vivo immunomodulating concept. Blood 2005; 
105:2287-93.
5. Haj M, Dasani H, Kundu S, Mohite U, Collins PW. Acquired 
haemophilia A may be associated with clopidogrel. BMJ 2004; 
329:323.
6. Franchini M, Capra F, Nicolini N, et al. Drug-induced anti-factor 
VIII antibodies: a systematic review. Med Sci Monit 2007;13: 
RA55-61.
7. Balamuthusamy S, Arora R. Hematologic adverse effects of 
clopidogrel. Am J Ther 2007;14:106-12.
8. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent 
Recurrent Events (CURE) trial programme; rationale, design and 
baseline characteristics including a meta-analysis of the effects of 
thienopyridines in vascular disease. Eur Heart J 2000;21:2033-41.
9. A randomised, blinded, trial of clopidogrel versus aspirin in 
patients at risk of ischaemic events (CAPRIE). CAPRIE Steering 
Committee. Lancet 1996;348:1329-39.
10. Elmi F, Peacock T, Schiavone J. Isolated profound thrombocy-
topenia associated with clopidogrel. J Invasive Cardiol 2000;12: 
532-5.
11. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic throm-
bocytopenic purpura associated with clopidogrel. N Engl J Med 
2000;342:1773-7.
12. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic 
thrombocytopenic purpura-hemolytic uremic syndrome. Curr 
Opin Hematol 2001;8:286-93.
13. Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin 
Haematol 1996;9:331-54.
14. Hay CR. Acquired haemophilia. Baillieres Clin Haematol 1998;11: 
287-303.
15. Green D, Blanc J, Foiles N. Spontaneous inhibitors of factor VIII: 
kinetics of inactivation of human and porcine factor VIII. J Lab 
Clin Med 1999;133:260-4.